Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadekinig alfa - AB2 Bio

Next Previous
Drug Profile

Tadekinig alfa - AB2 Bio

Alternative Names: IL-18BP - AB2 Bio; r-hIL-18BP; Recombinant human IL-18 binding protein - AB2 Bio

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AB2 Bio
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 1 inhibitors; Interleukin 18 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophagocytic lymphohistiocytosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunological disorders
  • Phase II Adult-onset Still's disease

Most Recent Events

  • 27 Jan 2025 Nippon Shinyaku enters option to license agreement with AB2 Bio for Tadekinig alfa in USA
  • 27 Jan 2025 AB2 Bio announces intention to submit BLA to US FDA for Immunological disorders
  • 27 Jan 2025 Tadekinig alfa receives Rare Paediatric Disease Designation for Immunological disorders in USA before January 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top